Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study

Antoinette J. Wozniak, John J. Crowley, Stanley P. Balcerzak, Geoffrey R. Weiss, C. Harris Spiridonidis, Laurence H. Baker, Kathy S. Albain, Karen Kelly, Sar A. Taylor, David R. Gandara, Robert B. Livingston

Research output: Contribution to journalArticle

498 Citations (Scopus)

Abstract

Purpose: Cisplatin has played a major role in the treatment of non- small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group (SWOG) to determine whether the combination of vinorelbine and cisplatin has any advantage with regard to response rate, survival, and time to treatment failure over single-agent cisplatin in the treatment of patients with advanced NSCLC . Methods: Between October 1993 and April 1995, 432 patients with advanced stage NSCLC were randomized to receive arm I (cisplatin 100 mg/m2 every 4 weeks) or arm II (cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly). All patients were chemotherapy-naive, had performance status (PS) 0 or 1, and had adequate hematologic, renal, and hepatic function. Results: Four hundred fifteen patients were eligible and assessable. On arm I (cisplatin), there was a 12% partial response rate. Arm II (cisplatin and vinorelbine) had a 26% response rate (2% complete responses and 24% partial responses, P = .0002). There was a statistically significant advantage with regard to progression-free survival (median, 2 v 4 months; P = .0001) and overall survival (median, 6 v 8 months; P = .0018) for the cisplatin and vinorelbine arm. One-year survival was 20% for cisplatin alone and 36% for the combination arm. There was more hematologic toxicity on arm II of the study (81% grades 3 and 4 granulocytopenia v 5% on arm I). Other toxicities, such as renal insufficiency, ototoxicity, and nausea and vomiting, and neuropathy were similar. Conclusion: The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisplatin in the treatment of advanced NSCLC. Cisplatin and vinorelbine is the new standard for SWOG against which new therapies will be evaluated.

Original languageEnglish (US)
Pages (from-to)2459-2465
Number of pages7
JournalJournal of Clinical Oncology
Volume16
Issue number7
StatePublished - Jul 1998

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Therapeutics
vinorelbine
Agranulocytosis
Survival
Treatment Failure
Nausea
Disease-Free Survival
Vomiting
Renal Insufficiency
Survival Rate
Kidney
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wozniak, A. J., Crowley, J. J., Balcerzak, S. P., Weiss, G. R., Spiridonidis, C. H., Baker, L. H., ... Livingston, R. B. (1998). Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. Journal of Clinical Oncology, 16(7), 2459-2465.

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer : A Southwest Oncology Group study. / Wozniak, Antoinette J.; Crowley, John J.; Balcerzak, Stanley P.; Weiss, Geoffrey R.; Spiridonidis, C. Harris; Baker, Laurence H.; Albain, Kathy S.; Kelly, Karen; Taylor, Sar A.; Gandara, David R.; Livingston, Robert B.

In: Journal of Clinical Oncology, Vol. 16, No. 7, 07.1998, p. 2459-2465.

Research output: Contribution to journalArticle

Wozniak, AJ, Crowley, JJ, Balcerzak, SP, Weiss, GR, Spiridonidis, CH, Baker, LH, Albain, KS, Kelly, K, Taylor, SA, Gandara, DR & Livingston, RB 1998, 'Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study', Journal of Clinical Oncology, vol. 16, no. 7, pp. 2459-2465.
Wozniak, Antoinette J. ; Crowley, John J. ; Balcerzak, Stanley P. ; Weiss, Geoffrey R. ; Spiridonidis, C. Harris ; Baker, Laurence H. ; Albain, Kathy S. ; Kelly, Karen ; Taylor, Sar A. ; Gandara, David R. ; Livingston, Robert B. / Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer : A Southwest Oncology Group study. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 7. pp. 2459-2465.
@article{c58868abc6354cbf990478933d2cee94,
title = "Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study",
abstract = "Purpose: Cisplatin has played a major role in the treatment of non- small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group (SWOG) to determine whether the combination of vinorelbine and cisplatin has any advantage with regard to response rate, survival, and time to treatment failure over single-agent cisplatin in the treatment of patients with advanced NSCLC . Methods: Between October 1993 and April 1995, 432 patients with advanced stage NSCLC were randomized to receive arm I (cisplatin 100 mg/m2 every 4 weeks) or arm II (cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly). All patients were chemotherapy-naive, had performance status (PS) 0 or 1, and had adequate hematologic, renal, and hepatic function. Results: Four hundred fifteen patients were eligible and assessable. On arm I (cisplatin), there was a 12{\%} partial response rate. Arm II (cisplatin and vinorelbine) had a 26{\%} response rate (2{\%} complete responses and 24{\%} partial responses, P = .0002). There was a statistically significant advantage with regard to progression-free survival (median, 2 v 4 months; P = .0001) and overall survival (median, 6 v 8 months; P = .0018) for the cisplatin and vinorelbine arm. One-year survival was 20{\%} for cisplatin alone and 36{\%} for the combination arm. There was more hematologic toxicity on arm II of the study (81{\%} grades 3 and 4 granulocytopenia v 5{\%} on arm I). Other toxicities, such as renal insufficiency, ototoxicity, and nausea and vomiting, and neuropathy were similar. Conclusion: The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisplatin in the treatment of advanced NSCLC. Cisplatin and vinorelbine is the new standard for SWOG against which new therapies will be evaluated.",
author = "Wozniak, {Antoinette J.} and Crowley, {John J.} and Balcerzak, {Stanley P.} and Weiss, {Geoffrey R.} and Spiridonidis, {C. Harris} and Baker, {Laurence H.} and Albain, {Kathy S.} and Karen Kelly and Taylor, {Sar A.} and Gandara, {David R.} and Livingston, {Robert B.}",
year = "1998",
month = "7",
language = "English (US)",
volume = "16",
pages = "2459--2465",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer

T2 - A Southwest Oncology Group study

AU - Wozniak, Antoinette J.

AU - Crowley, John J.

AU - Balcerzak, Stanley P.

AU - Weiss, Geoffrey R.

AU - Spiridonidis, C. Harris

AU - Baker, Laurence H.

AU - Albain, Kathy S.

AU - Kelly, Karen

AU - Taylor, Sar A.

AU - Gandara, David R.

AU - Livingston, Robert B.

PY - 1998/7

Y1 - 1998/7

N2 - Purpose: Cisplatin has played a major role in the treatment of non- small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group (SWOG) to determine whether the combination of vinorelbine and cisplatin has any advantage with regard to response rate, survival, and time to treatment failure over single-agent cisplatin in the treatment of patients with advanced NSCLC . Methods: Between October 1993 and April 1995, 432 patients with advanced stage NSCLC were randomized to receive arm I (cisplatin 100 mg/m2 every 4 weeks) or arm II (cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly). All patients were chemotherapy-naive, had performance status (PS) 0 or 1, and had adequate hematologic, renal, and hepatic function. Results: Four hundred fifteen patients were eligible and assessable. On arm I (cisplatin), there was a 12% partial response rate. Arm II (cisplatin and vinorelbine) had a 26% response rate (2% complete responses and 24% partial responses, P = .0002). There was a statistically significant advantage with regard to progression-free survival (median, 2 v 4 months; P = .0001) and overall survival (median, 6 v 8 months; P = .0018) for the cisplatin and vinorelbine arm. One-year survival was 20% for cisplatin alone and 36% for the combination arm. There was more hematologic toxicity on arm II of the study (81% grades 3 and 4 granulocytopenia v 5% on arm I). Other toxicities, such as renal insufficiency, ototoxicity, and nausea and vomiting, and neuropathy were similar. Conclusion: The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisplatin in the treatment of advanced NSCLC. Cisplatin and vinorelbine is the new standard for SWOG against which new therapies will be evaluated.

AB - Purpose: Cisplatin has played a major role in the treatment of non- small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group (SWOG) to determine whether the combination of vinorelbine and cisplatin has any advantage with regard to response rate, survival, and time to treatment failure over single-agent cisplatin in the treatment of patients with advanced NSCLC . Methods: Between October 1993 and April 1995, 432 patients with advanced stage NSCLC were randomized to receive arm I (cisplatin 100 mg/m2 every 4 weeks) or arm II (cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly). All patients were chemotherapy-naive, had performance status (PS) 0 or 1, and had adequate hematologic, renal, and hepatic function. Results: Four hundred fifteen patients were eligible and assessable. On arm I (cisplatin), there was a 12% partial response rate. Arm II (cisplatin and vinorelbine) had a 26% response rate (2% complete responses and 24% partial responses, P = .0002). There was a statistically significant advantage with regard to progression-free survival (median, 2 v 4 months; P = .0001) and overall survival (median, 6 v 8 months; P = .0018) for the cisplatin and vinorelbine arm. One-year survival was 20% for cisplatin alone and 36% for the combination arm. There was more hematologic toxicity on arm II of the study (81% grades 3 and 4 granulocytopenia v 5% on arm I). Other toxicities, such as renal insufficiency, ototoxicity, and nausea and vomiting, and neuropathy were similar. Conclusion: The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisplatin in the treatment of advanced NSCLC. Cisplatin and vinorelbine is the new standard for SWOG against which new therapies will be evaluated.

UR - http://www.scopus.com/inward/record.url?scp=0031861215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031861215&partnerID=8YFLogxK

M3 - Article

C2 - 9667264

AN - SCOPUS:0031861215

VL - 16

SP - 2459

EP - 2465

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -